CNP-1001

CNP-1001 is a preclinical-stage therapeutic candidate developed by SiNON Nano Sciences, featuring C-type natriuretic peptide (CNP) delivered via a specialized carbon nanoparticle (CNP) platform. The core technology involves functionalized carbon nanoparticles designed to traverse the blood-brain barrier (BBB), a major obstacle in treating central nervous system disorders. By utilizing this delivery system, CNP-1001 aims to provide therapeutic levels of C-type natriuretic peptide directly to the brain, where it acts as an agonist for the natriuretic peptide receptor 2 (NPR2). This mechanism is being explored for the treatment of various neurological conditions that require targeted peptide delivery to the brain.

Other names

c-type natriuretic peptide-carbon nanoparticleCNP-SiNON